ARTICLE | Clinical News
AZP-531: Phase IIa started
March 30, 2015 7:00 AM UTC
Alize began a double-blind, placebo-controlled, European Phase IIa trial to evaluate 2, 3 and 4 mg subcutaneous AZP-531 given once daily for 2 weeks in up to 40 patients. ...